Abstract B*38:01 and B*39:06 are present with phenotypic frequencies <2 %
Type 1 diabetes is characterized by the T cell-mediated destruction of the insulin-producing beta cells (Bettini and Vignali 2011; Walter and Santamaria 2005) . In both humans and non-obese diabetic mice, CD8 T cell recognition of specific peptide-class I MHC complexes is essential to this process (Coppieters et al. 2012; Knight et al. 2013; Serreze et al. 1994) . In an inflammatory context, autoreactive CD8 T cells recognize beta cell epitopes presented both by professional antigen presenting cells and by the beta cells themselves, resulting in the destruction of the beta cells (Walter and Santamaria 2005) . Alternatively, under non-inflammatory conditions, potential autoreactive CD8 T cells may be eliminated either centrally or peripherally following recognition of beta cell peptides; this elimination contributes to the prevention of type 1 diabetes (Brims et al. 2010; Rosmalen et al. 2002; Srinivasan and Frauwirth 2009; Workman et al. 2009 ). For example, beta cell epitopes may be presented to CD8 T cells by dendritic cells in a tolerogenic manner, Electronic supplementary material The online version of this article (doi:10.1007/s00251-015-0898-2) contains supplementary material, which is available to authorized users. resulting in T cell deletion and/or anergy (Steinman et al. 2003) .
As CD8 T cell recognition of specific epitopes is important for both type 1 diabetes pathogenesis and prevention of disease, it is unsurprising that a number of type 1 diabetesrelevant class I HLA alleles have been identified. Of these, HLA-B*39:06 is the HLA-B allele most associated with disease progression; it is also associated with an early age of disease onset (Howson et al. 2009; Nejentsev et al. 2007; Noble et al. 2010) . HLA-B*38:01 is the HLA-B allele most associated with protection from type 1 diabetes (Howson et al. 2009; Nejentsev et al. 2007 ). The vastly different disease association of these two alleles is surprising as both are members of the B27 supertype and, as such, are predicted to have similar peptide repertoires (Eichmann et al. 2014; Falk et al. 1995; Sidney et al. 2008b ). However, while HLA-B*39:06 and HLA-B*38:01 share 97.6 % amino acid sequence identity, their sequence differences appear at residues predicted to be involved in peptide binding pockets. The pocket most affected by these differences appears to be the F pocket, involved in binding to the C-terminal position of the peptide, though other pockets along the peptide-binding groove appear to be affected as well (Matsumura et al. 1992; Saper et al. 1991) . These changes in sequence can significantly affect the preferred anchor residues for these MHCs, thereby changing their peptide binding repertoires. This in turn can result in HLA-B*39:06 and HLA-B*38:01 presenting different disease-relevant beta cell epitopes, which will impact the resultant islet CD8 T cell population.
In order to better understand the differential effects of these two highly similar MHCs on disease pathogenesis, deeper knowledge of their peptide-binding characteristics is essential. For example, the identification of each MHC's preferred anchor residues will be useful as a guide towards rationally designed beta cell epitope identification strategies. This is necessary as epitope identification is essential for designing novel therapies and diagnostic techniques. Finally, while the comparison between the HLA-B*39:06 and HLA-B*38:01 is important in the study of type 1 diabetes, the relevance of the work presented here is not limited to this disease. Both MHCs have been linked to a variety of other autoimmune diseases. HLA-B*39:06 has been associated with a risk for Takayasu arteritis (Rodriguez-Reyna et al. 1998; Salazar et al. 2000; Vargas-Alarcon et al. 2005) . Preliminary studies have linked HLA-B*38:01 to multiple sclerosis and to protection from pemphigus vulgaris (Khankhanian et al. 2015; Mortazavi et al. 2013) .
To characterize the specificity of these alleles, highthroughput peptide-binding assays, based on the use of purified MHC molecules and high affinity radiolabeled ligands, were developed and performed for both alleles following previously detailed methodologies (Sidney et al. 2013) . B*38:01 MHC molecules were purified from the EBV transformed homozygous line TEM (IHW 9057), and peptide YHIPGDTLF (Variola virus RNA-helicase 346-354; IC50 1.4 nM) was used as the radiolabeled probe. B*39:06 molecules were purified (Sidney et al. 2013 ) from a single allele transfected C1R line, and peptide FRYQGHVGA (Homo sapiens proteasome subunit 127-135; IC50 24 nM), endogenously bound and eluted from B*39:06 molecules (data not shown), was used as the radiolabeled probe.
To probe the specificity of B*38:01, a panel of single amino acid substitution analogs (SAAS) of the human ribosomal protein L9 39-47 peptide (sequence NHINVELSL; IC50 68 nM) was synthesized. The panel represented a complete scan of each position with substitution to each of the 20 naturally occurring amino acids. The measured IC50 nM values for each individual peptide are shown in Supplemental Table  1 . The IC50 nM value for each substituted peptide was standardized as a ratio to the IC50 nM of the wild type peptide (Table 1) . Finally, and as done previously with similar data (Reed et al. 2011; Sidney et al. 2008a ), we calculated for each position a ratio of the (geometric) average relative binding (ARB) of all substitutions at a given position to the affinity of the wild type peptide. This ratio, denominated the specificity factor (SF), identifies the positions where the majority of residues are associated with significant decreases in binding capacity; that is, positions with the highest specificity will have the highest SF value.
With these considerations, B*38:01 was found to utilize the residues in position 2 and at the C-terminus, associated with a SF of 22.5 and 12.5, respectively, as primary anchors. No other position was found to have a SF > 1. At position 2, 12 different substitutions were associated with >50-fold decreases in B*38:01 binding capacity, and H and R, with ARB of 1 and 0.93, respectively, were the most preferred residues. Q, with an ARB of 0.13, was also tolerated. All other substitutions at position 2 were associated with >10-fold decreases in binding affinity.
At the C-terminus, 10 residues were associated with >50-fold changes in B*38:01 affinity. Here, the large hydrophobic residues I, F, and L were the most preferred, with ARB of 13, 1.4, and 1, respectively. Two other large hydrophobic residues, W and M, were also tolerated, with ARB in the 0.1-1 range.
At both positions 1 and 3, four different residues had >10-fold effects on binding, suggesting that these may be weak secondary anchors. Only a few substitutions at other positions were associated with >10-fold increases or decreases in B*38:01 binding affinity, suggesting that B*38:01 binding capacity is not generally highly dependent upon secondary anchor interactions. A summary B*38:01 motif, highlighting the most prominent influences on binding capacity, is shown in Fig. 1 (upper panel) .
Following the same approach, a SAAS panel of the Mus musculus proteasome subunit 117-125 peptide (IC50 24 nM) was synthesized, tested for binding to B*39:06, a n d t h e d a t a a n a l y z e d a s a b o v e ( Ta b l e 2 a n d Supplemental Table 2 ). Like B*38:01, B*39:06 was found to utilize position 2 and the C-terminus as its main anchors. Position 2, where 13 residues were associated with >50-fold decreases in binding capacity, had a SF of 9.85. Here, R and M with ARB of 1 and 0.45, respectively, were the most preferred residues, and K and Q (ARB in the 0.1-0.15 range) were tolerated.
The C-terminus had a SF of 4.39, and nine residues caused >50-fold decreases in binding. The small residue A (ARB = 1) was the most preferred at the C-terminus, followed by other small residues G and V, with ARB of 0.46 and 0.25, respectively. The small polar residues S and T, and the aliphatic residue I, were also tolerated, with ARB in the 0.1-0.2 range.
Position 3 was found to have a SF of 3.49, and six substitutions were associated with >50-fold decreases on B*39:06 binding capacity, suggesting that position 3 is a dominant secondary anchor. Here, the aromatic/large hydrophobic residues W, Y, M, and F, and P and C, were the most preferred. At position 1, there were six additional >10-fold deleterious effects on binding, suggesting this position may function as a weak secondary anchor; the aromatic/large hydrophobic residues W, Y, M, and F were the most preferred here also. A summary B*39:06 motif, highlighting the most prominent influences on binding capacity, is shown in Fig. 1 (lower panel) . A previous study by Eichmann et al. (2014) reported the basic primary anchor motifs for B*38:01 and B*39:06 based on sequence analyses of eluted peptides. In that study, B*38:01 was found to preferentially bind ligands with H (and secondarily, Q) in position 2 and L (and secondarily I and F) at the C-terminus, a motif that is largely in agreement with one defined by Falk et al. (1995) , also based on peptide elution. B*39:06 was reported as preferring ligands with R and H in position 2 and A and V at the C-terminus. These motifs are largely in agreement with the respective motifs delineated herein.
In conclusion, the present study has characterized the peptide binding specificity of the HLA class I alleles B*38:01 and B*39:06. Confirming previous predictions, both alleles were found to recognize a motif that largely overlaps with the HLA B27 supermotif (Sette and Sidney 1999) . The present study also confirms for both alleles previously defined main anchor specificity and extends their utility by providing a more detailed quantitative motif, inclusive of influences of all 20 naturally occurring residues at each position. It is hoped that these more detailed motifs for two alleles with diametrically opposed associations with type 1 diabetes will facilitate future efforts to elucidate the T cell mechanisms involved in the disease. Encouragingly, the validation of predictions with small pilot sets of about 30 peptides each (Supplemental Table 3 ) returned area-under-the-curve (AUC) values from receiver-operating-curve (ROC) analyses of 0.852 and 0.833 for B*38:01 and B39:06, respectively. These performances compare very favorably with predictions on extensively characterized alleles done with more advanced bioinformatic approaches Trolle et al. 2015) . Whether predicted binding peptides will be efficiently generated by natural processing is unknown. However, it has been shown in the context of many pathogens, including HCV, HIV, SIV, P. falciparum, and vaccinia, that CTL epitopes can be identified using a motif-/algorithmbased approach (see, e.g., (Doolan et al. 2003; Sette 2000 ; Fig. 1 Sette and Fikes 2003; Sette et al. 2001; Sette and Peters 2007; Sette and Rappuoli 2010) ), as binding to MHC is a necessary requirement for a peptide to elicit a T cell response. We also note the previous data from our group indicating that, in the case of infectious diseases, the majority of epitopes can be identified by selecting peptides scoring in the top 1-2 % of all peptides (Moutaftsi et al. 2006) . We have also identified epitopes targeted by autoreactive CD8 T cells based on predicted binding affinities (Mukherjee et al. 2015) . Thus, our report of quantitative peptide-binding motifs for B*38:01 and B*39:06 should facilitate the identification of T cell epitopes derived either from autoantigens or from microbes. Table 1 Preferred residues at the position 2 and C-terminus main anchor positions are highlighted by italicized font (see also legend for Table 1) 
